Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization M…
Overview
Roche is a pharmaceutical and diagnostics company that focused on improving people’s lives. Roche is the owner of F. Hoffmann-La Roche Ltd. Roche is a provider of in-vitro diagnostics and drugs for cancer and transplantation. It specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. F. Hoffmann-La Roche Ltd. serves hospitals, research labs, private medical labs, practicing physicians, and patients. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera which are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. F. Hoffmann-La Roche Ltd. also conducts research and development as well as production related to molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostics and research.
Tech Stack
Funding History
Post Ipo Equity
$2.8B
May 2001
Novartis
Post Ipo Equity
Undisclosed
Jan 2010
Post Ipo Equity
$500K
May 2020
SCALE AI
Post Ipo Equity
$5.0B
Aug 2021
SoftBank